Because sorafenib is designed to block the RAF/MEK/ERK pathway and induce tumor inhibition in HCC, the reactivation of ERK pathway confers an acquired resistance to BRAF and MEK inhibitors 23. This evidence concerns the gene BRAF and neoplasm.